Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.57 |
| ▸ | AKT1 | P31749 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202299 | 0.89 | RAB9A (0.67) | LMNAKMT2AMAPTPOLBGAA | |
| SCHEMBL5205367 | 0.85 | LMNA (0.66) | LMNAKMT2AMAPTPOLBGAA | |
| SCHEMBL19745233 | 0.85 | RAB9A (0.64) | LMNAKMT2AMAPTPOLBGAA | |
| SCHEMBL5239760 | 0.81 | DPP4 (0.56) | LMNAKMT2AMAPTPOLBGAA | |
| SCHEMBL5142677 | 0.80 | EPHX2 (0.72) | LMNAKMT2AMAPTPOLBMEN1 | |
| SCHEMBL31236338 | 0.80 | MAPT (0.77) | KMT2AMAPTGAAMEN1XBP1 | |
| SCHEMBL5142590 | 0.80 | MAPT (0.77) | KMT2AMAPTGAAMEN1XBP1 | |
| SCHEMBL20827274 | 0.79 | RAB9A (0.78) | LMNAKMT2ATRPV4MAPTPOLB | |
| SCHEMBL18657815 | 0.78 | EPHX2 (0.80) | LMNAKMT2AMAPTPOLBMEN1 | |
| SCHEMBL965744 | 0.76 | LMNA (0.55) | LMNAKMT2AAKT1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554246-B1 | DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| EP-1554246-B1 | DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20060100207-A1 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
| EP-1554246-A2 | DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS | Bayer HealthCare AG (DE) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004020410-A2 | DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004020410-A2 | DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100207-A1 | Dihydropyridinone derivatives | TNNI3, DHPS, TNNT2 | LMNA 2783/4885KMT2A 2664/4885TRPV4 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.